After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Zai Lab Limited ADR is $2.05B. A total of 0.73 million shares were traded on the day, compared to an average of 653.99K shares.
In the most recent transaction, Du Ying sold 8,380 shares of ZLAB for 26.12 per share on Jan 03. After the transaction, the Chairperson & CEO now owns 1,133,450 company shares. In a previous transaction on Jan 03, Edmondson Frazor Titus III sold 4,803 shares at 26.12 per share. ZLAB shares that Chief Legal Officer owns now total 30,005.
Among the insiders who sold shares, Reinhart Harald disposed of 4,803 shares on Jan 03 at a per-share price of $26.12. This resulted in the insider holding 46,060 shares of ZLAB after the transaction. In another insider transaction, Amado Rafael sold 19,363 shares at $26.30 per share on Jan 02. Company shares held by the insider now total 22,637.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ZLAB in the last 3 months, the mean price target is $59.22 with high estimates of $123.00 and low estimates of $31.00. In terms of 52-week highs and lows, ZLAB has a high of $41.79 and a low of $17.68.
As of this writing, ZLAB has an earnings estimate of -$0.77 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.72 per share and a lower estimate of -$0.85. The company reported an EPS of -$0.71 in the last quarter, which was 31.70% higher than expectations of -$1.04.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ZLAB’s latest balance sheet shows that the firm has $1.41B in Cash & Short Term Investments as of fiscal 2021. There were $15.54M in debt and $192.90M in liabilities at the time. Its Book Value Per Share was $8.19, while its Total Shareholder’s Equity was $1.38B.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZLAB is Buy with a score of 5.00.
